Clinical Trials Browser

Phase 2 × Unknown × Breast × Clear all

NCT06678230 2024-11-07

Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT06311695 2024-06-24

CESM

Phase 2 Unknown

Breast Neoplasms

NCT06375707 2024-04-19

Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

Phase 2 Unknown

Advanced Breast Cancer

NCT05925257 2024-04-17

Digital Health Intervention to Improve Health Care and Outcomes for Breast Cancer Patients

Phase 2 Unknown

Breast Neoplasms

NCT05659056 2024-04-16

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

Phase 2 Unknown

Pathologic Complete Response, Breast Neoplasms

NCT05145907 2024-04-15

Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors

Phase 2 Unknown

BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms

NCT03639948 2024-04-11

NeoPACT

Phase 2 Unknown

120 enrolled 12 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06341842 2024-04-02

PROTECT

Phase 2 Unknown

Breast Neoplasms, Cardiotoxicity

NCT06176339 2024-03-15

Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients"

Phase 2 Unknown

Breast Cancer Female

NCT04739670 2024-03-01

BELLA

Phase 2 Unknown

Recurrence, Triple Negative Breast Neoplasms

NCT04537286 2024-02-26

First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients

Phase 2 Unknown

Breast Neoplasms

NCT03924466 2024-02-16

VUBAR

Phase 2 Unknown

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT03818685 2024-02-12

BreastImmune03

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05880394 2024-02-12

Study of Dotatate Imaging in Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT05042791 2024-02-09

A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases

Phase 2 Unknown

HER2-positive Metastatic Breast Cancer

NCT04824014 2024-02-06

4FMFES-PET Imaging of ER+ Advanced Breast Cancers

Phase 2 Unknown

ER+ Breast Cancer

NCT05496101 2024-02-05

CLI-FAR

Phase 2 Unknown

Breast Cancer Female

NCT05266937 2024-02-01

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05640778 2024-01-31

Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)

Phase 2 Unknown

Luminal B/HER2-negative Breast Cancer

NCT04914390 2024-01-22

NeoATCT

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT05629429 2024-01-17

Olaparib Maintenance Therapy in Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT04395989 2023-12-22

FUTURE-SUPER

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT03812393 2023-12-18

FACT-2

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04197687 2023-12-18

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Phase 2 Unknown

Breast Neoplasms

NCT06152822 2023-12-01

Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases

Phase 2 Unknown

Brain Neoplasms, Breast Neoplasms

NCT06154109 2023-12-01

Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT06151249 2023-11-30

Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy

Phase 2 Unknown

Breast Neoplasms, Fatigue

NCT03906669 2023-11-22

WinPro

Phase 2 Unknown

Breast Neoplasms

NCT04734262 2023-11-18

SPARK

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06133088 2023-11-15

Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.

Phase 2 Unknown

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed

NCT04267315 2023-10-16

Trigger Point Injections for Post-Mastectomy Pain Syndrome

Phase 2 Unknown

Breast Neoplasms, Myofascial Pain Syndromes

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT04883814 2023-09-28

18F-fluoroestradiol (FES) PET/CT for Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT05174832 2023-09-28

Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

Phase 2 Unknown

Triple Negative Breast Neoplasms

NCT05800834 2023-09-28

MorphineGEL

Phase 2 Unknown

BreastHead & Neck

Cancer Pain, Breast Neoplasms, Head and Neck Neoplasms, Wounds and Injuries

NCT03691051 2023-09-25

A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

Phase 2 Unknown

HER2 Positive Metastatic Breast Cancer

NCT04681287 2023-09-25

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

Phase 2 Unknown

HER2 Positive Metastatic Breast Cancer

NCT05296577 2023-09-25

Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT05328440 2023-09-25

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Phase 2 Unknown

Breast Neoplasms

NCT03712956 2023-09-21

CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER

Phase 2 Unknown

Breast Neoplasms

NCT04165993 2023-09-21

Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT05353361 2023-09-15

A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT05823623 2023-09-14

Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Phase 2 Unknown

Breast Cancer Metastatic

NCT06000033 2023-08-21

Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT03961698 2023-08-14

MARIO-3

Phase 2 Unknown

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT05967884 2023-08-01

PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT05969184 2023-08-01

Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC

Phase 2 Unknown

Breast Neoplasm Female

NCT05966441 2023-07-28

Role of Curcumin in Paclitaxel Induced PN

Phase 2 Unknown

Breast Neoplasms

NCT05945368 2023-07-14

A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC

Phase 2 Unknown

HER2-positive Breast Cancer